Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia

R. S. Benjamin, M. J. Keating, M. Valdivieso, K. B. McCredie, Robert B Livingston, M. A. Burgess, V. Rodriguez, G. P. Bodey, J. A. Gottlieb

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Piperazinedione was administered to 79 patients with solid tumors on an intermittent schedule with single doses of 1.5-36 mg/m 2. Courses were usually repeated at 4-week intervals. Twenty-five patients with leukemia were treated at doses of 18-36 mg/m 2 (occasionally for 2 successive days) every 1-4 weeks. Of 48 evaluable patients with malignant melanoma, three (6%) achieved partial remission and nine (20%) had stable disease. Eight of 17 (47%) patients with adenocarcinomas and one of two (50%) patients with lymphomas also had stable disease. Six of 14 (43%) patients with acute myelogenous leukemia showed hematologic improvement, as did one of 11 (9%) patients with blast cell crisis of chronic myelogenous leukemia. The principal toxic effect was myelosuppression, which occurred in 69% of the patients with solid tumors. Profound bone marrow aplasia occurred in 19% of the patients, resulting in six deaths (8%). Risk factors for marrow aplasia included extensive prior therapy, prior nitrosoureas, cumulative toxicity from piperazinedione, and abnormal liver function tests. The recommended doses for further studies are 9 mg/m 2 for patients with risk factors for marrow aplasia, 12 mg/m 2 for patients with prior therapy, 15 mg/m 2 for previously untreated patients, and 24-36 mg/m 2 for patients with acute leukemia.

Original languageEnglish (US)
Pages (from-to)939-943
Number of pages5
JournalCancer Treatment Reports
Volume63
Issue number6
StatePublished - 1979
Externally publishedYes

Fingerprint

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Leukemia
Neoplasms
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Benjamin, R. S., Keating, M. J., Valdivieso, M., McCredie, K. B., Livingston, R. B., Burgess, M. A., ... Gottlieb, J. A. (1979). Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. Cancer Treatment Reports, 63(6), 939-943.

Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. / Benjamin, R. S.; Keating, M. J.; Valdivieso, M.; McCredie, K. B.; Livingston, Robert B; Burgess, M. A.; Rodriguez, V.; Bodey, G. P.; Gottlieb, J. A.

In: Cancer Treatment Reports, Vol. 63, No. 6, 1979, p. 939-943.

Research output: Contribution to journalArticle

Benjamin, RS, Keating, MJ, Valdivieso, M, McCredie, KB, Livingston, RB, Burgess, MA, Rodriguez, V, Bodey, GP & Gottlieb, JA 1979, 'Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia', Cancer Treatment Reports, vol. 63, no. 6, pp. 939-943.
Benjamin RS, Keating MJ, Valdivieso M, McCredie KB, Livingston RB, Burgess MA et al. Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. Cancer Treatment Reports. 1979;63(6):939-943.
Benjamin, R. S. ; Keating, M. J. ; Valdivieso, M. ; McCredie, K. B. ; Livingston, Robert B ; Burgess, M. A. ; Rodriguez, V. ; Bodey, G. P. ; Gottlieb, J. A. / Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 6. pp. 939-943.
@article{8cddabda8a1143789cd04ac9371d6022,
title = "Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia",
abstract = "Piperazinedione was administered to 79 patients with solid tumors on an intermittent schedule with single doses of 1.5-36 mg/m 2. Courses were usually repeated at 4-week intervals. Twenty-five patients with leukemia were treated at doses of 18-36 mg/m 2 (occasionally for 2 successive days) every 1-4 weeks. Of 48 evaluable patients with malignant melanoma, three (6{\%}) achieved partial remission and nine (20{\%}) had stable disease. Eight of 17 (47{\%}) patients with adenocarcinomas and one of two (50{\%}) patients with lymphomas also had stable disease. Six of 14 (43{\%}) patients with acute myelogenous leukemia showed hematologic improvement, as did one of 11 (9{\%}) patients with blast cell crisis of chronic myelogenous leukemia. The principal toxic effect was myelosuppression, which occurred in 69{\%} of the patients with solid tumors. Profound bone marrow aplasia occurred in 19{\%} of the patients, resulting in six deaths (8{\%}). Risk factors for marrow aplasia included extensive prior therapy, prior nitrosoureas, cumulative toxicity from piperazinedione, and abnormal liver function tests. The recommended doses for further studies are 9 mg/m 2 for patients with risk factors for marrow aplasia, 12 mg/m 2 for patients with prior therapy, 15 mg/m 2 for previously untreated patients, and 24-36 mg/m 2 for patients with acute leukemia.",
author = "Benjamin, {R. S.} and Keating, {M. J.} and M. Valdivieso and McCredie, {K. B.} and Livingston, {Robert B} and Burgess, {M. A.} and V. Rodriguez and Bodey, {G. P.} and Gottlieb, {J. A.}",
year = "1979",
language = "English (US)",
volume = "63",
pages = "939--943",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia

AU - Benjamin, R. S.

AU - Keating, M. J.

AU - Valdivieso, M.

AU - McCredie, K. B.

AU - Livingston, Robert B

AU - Burgess, M. A.

AU - Rodriguez, V.

AU - Bodey, G. P.

AU - Gottlieb, J. A.

PY - 1979

Y1 - 1979

N2 - Piperazinedione was administered to 79 patients with solid tumors on an intermittent schedule with single doses of 1.5-36 mg/m 2. Courses were usually repeated at 4-week intervals. Twenty-five patients with leukemia were treated at doses of 18-36 mg/m 2 (occasionally for 2 successive days) every 1-4 weeks. Of 48 evaluable patients with malignant melanoma, three (6%) achieved partial remission and nine (20%) had stable disease. Eight of 17 (47%) patients with adenocarcinomas and one of two (50%) patients with lymphomas also had stable disease. Six of 14 (43%) patients with acute myelogenous leukemia showed hematologic improvement, as did one of 11 (9%) patients with blast cell crisis of chronic myelogenous leukemia. The principal toxic effect was myelosuppression, which occurred in 69% of the patients with solid tumors. Profound bone marrow aplasia occurred in 19% of the patients, resulting in six deaths (8%). Risk factors for marrow aplasia included extensive prior therapy, prior nitrosoureas, cumulative toxicity from piperazinedione, and abnormal liver function tests. The recommended doses for further studies are 9 mg/m 2 for patients with risk factors for marrow aplasia, 12 mg/m 2 for patients with prior therapy, 15 mg/m 2 for previously untreated patients, and 24-36 mg/m 2 for patients with acute leukemia.

AB - Piperazinedione was administered to 79 patients with solid tumors on an intermittent schedule with single doses of 1.5-36 mg/m 2. Courses were usually repeated at 4-week intervals. Twenty-five patients with leukemia were treated at doses of 18-36 mg/m 2 (occasionally for 2 successive days) every 1-4 weeks. Of 48 evaluable patients with malignant melanoma, three (6%) achieved partial remission and nine (20%) had stable disease. Eight of 17 (47%) patients with adenocarcinomas and one of two (50%) patients with lymphomas also had stable disease. Six of 14 (43%) patients with acute myelogenous leukemia showed hematologic improvement, as did one of 11 (9%) patients with blast cell crisis of chronic myelogenous leukemia. The principal toxic effect was myelosuppression, which occurred in 69% of the patients with solid tumors. Profound bone marrow aplasia occurred in 19% of the patients, resulting in six deaths (8%). Risk factors for marrow aplasia included extensive prior therapy, prior nitrosoureas, cumulative toxicity from piperazinedione, and abnormal liver function tests. The recommended doses for further studies are 9 mg/m 2 for patients with risk factors for marrow aplasia, 12 mg/m 2 for patients with prior therapy, 15 mg/m 2 for previously untreated patients, and 24-36 mg/m 2 for patients with acute leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0018733299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018733299&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 939

EP - 943

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -